anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 220,261-220,290
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

220,261-220,290 of 303,780

filter-aware
04
The slide uses a process-oriented layout to highlight vertical integration.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a Gantt-style visualization to represent clinical trial progress.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a two-column layout to contrast supply partnerships with internal manufacturing infrastructure.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Solution1 hit
07
Includes a logo grid of past/affiliated companies at the bottom.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Team1 hit
09
Includes a clinical imaging case study (A-D) showing patient response over time.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
10
Includes specific clinical study citation (Zacherl et al. 2021).Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
11
Includes competitive benchmarking context in the footer notes regarding Endocyte and POINT clinical trial data sizes.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
13
The slide outlines a standard 3+3 dose escalation clinical trial design for a radiopharmaceutical.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
14
Fusion Pharmaceuticals | Investor Presentation Deck | 33 slidesFusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
15
The slide uses a waterfall plot comparison to contrast clinical outcomes of two different therapeutic modalities.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
17
The slide uses a process flow diagram to map out different study arms (Single Ascending Dose, CASS, Multiple Dose Escalation, and Cold/Hot Dosing).Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
18
FPI-1434 clinical data presentation.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
19
The slide outlines two main pillars of the collaboration: targeted alpha therapies and combination therapies.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
20
The slide uses a Y-shaped antibody diagram to illustrate bispecific binding.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
21
The slide highlights a 'vaccine effect' in 13/15 animals and mentions IP protection for these combinations.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
22
Fusion Pharmaceuticals | Investor Presentation Deck | 33 slidesFusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
23
The slide provides a snapshot of the company's financial health and capital structure.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
24
Fusion Pharmaceuticals | Investor Presentation Deck | 33 slidesFusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
25
Fusion Pharmaceuticals | Investor Presentation Deck | 33 slidesFusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
26
Fusion Pharmaceuticals | Investor Presentation Deck | 33 slidesFusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
27
The slide uses medical imaging (SPECT/CT) to visually demonstrate the efficacy of a pharmacological strategy.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
28
The slide uses two line charts with error bars to demonstrate the therapeutic index improvement of the cold+hot regimen.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
29
Includes specific highlighting boxes (green and red) around data columns.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
30
Includes SPECT/CT imaging evidence showing increased lesion uptake with the cold/hot regimen.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
32
The slide uses a potency spectrum chart to frame the problem of toxin evolution and a comparison table to highlight the competitive advantages of TATs.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
33
The slide uses a combination of a biological process diagram and a line chart to demonstrate the competitive advantage of the proprietary linker technology.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
02
GMS | Investor Presentation Deck | 25 slidesGMS | Investor Presentation Deck | 25 slides · GMS
Pitch deck Investor relations 1 hit
03
The slide uses a grid of metrics to summarize company performance and scale.GMS | Investor Presentation Deck | 25 slides · GMS
Pitch deck Investor relations Beat · Problem1 hit
05
GMS | Investor Presentation Deck | 25 slidesGMS | Investor Presentation Deck | 25 slides · GMS
Pitch deck Investor relations Beat · Product1 hit
06
The slide uses a logo grid to demonstrate the 'local brand' aspect of their strategy and a map to show geographic coverage.GMS | Investor Presentation Deck | 25 slides · GMS
Pitch deck Investor relations Beat · Product1 hit